Researchers at Oregon State University are developing a novel drug delivery system with the potential to revolutionize treatment for a vast range of diseases, from genetic disorders like Huntington’s disease to infectious threats like COVID-19. The work, led by Hong Moulton at the Carlson College of Veterinary Medicine, centers on a technology using molecules called morpholinos – synthetic compounds designed to alter gene expression – and getting them precisely where they need to go within the body’s cells.
The challenge isn’t creating the morpholinos themselves, but ensuring they reach their targets effectively. These molecules work by binding to RNA, the messenger that carries genetic instructions, and can be tailored to either activate or deactivate specific genes, or even block viral replication. While morpholino-based drugs have already received FDA approval for some conditions, their delivery to targeted tissues has remained a significant hurdle. Moulton’s team aims to overcome this limitation, paving the way for what they describe as “universal genetic medicine.”
“What we’re doing is the next generation of this type of universal therapeutics,” explained Scott Bittner, a postdoctoral scholar in Moulton’s lab. “We’re making it so you can receive significant amounts of a drug into targeted tissue and get really specific effects. It’s sort of the front end of what’s going to become universal genetic medicine.” The team’s approach focuses on building delivery platforms that can navigate the complex cellular environment, overcoming barriers like the cell membrane and internal compartments called endosomes to deliver the therapeutic “warhead” directly to the cytoplasm and nucleus.
Image
Early Successes and Unexpected Setbacks
The OSU team has already demonstrated the effectiveness of one of their delivery platforms against SARS-CoV-2, the virus responsible for COVID-19. In 2024, they developed a morpholino that successfully inhibited the growth of multiple variants of the virus, as published in PLOS Pathogens. However, this five-year research project was abruptly terminated two years early last April due to cuts in federal research funding, according to the researchers.
The stability of morpholinos once inside cells is a key advantage of this approach. Unlike some other therapeutic molecules, morpholinos can persist for extended periods without degrading, potentially reducing the frequency of required doses and lowering treatment costs. Previous studies conducted by Moulton’s team showed sustained activity for up to 17 weeks after just four initial daily doses in animal models.
Current Research: From Lilly Partnerships to National Security
Moulton’s lab is currently pursuing two major grant-funded projects. One, in collaboration with pharmaceutical giant Eli Lilly, focuses on testing different antibody-based platforms to improve morpholino delivery. The goal is to refine the targeting mechanisms and ensure the molecules reach the intended tissues with precision.
The second project, funded by the U.S. Department of Defense, is tackling a particularly challenging target: the brain. Researchers are developing a delivery system to treat the Powassan virus, a tickborne pathogen that can cause severe neurological illness and, in many cases, is fatal. The Centers for Disease Control and Prevention (CDC) notes that the geographic range of Powassan virus is expanding due to climate change, increasing the risk of infection. The CDC currently states We find no antiviral treatments available for Powassan virus.
Crossing the blood-brain barrier, a protective mechanism that shields the brain from harmful substances, presents a significant obstacle. “It’s a lot trickier than delivering a morpholino into the respiratory system via nasal spray to target SARS-CoV-2,” Moulton acknowledged. However, early results from Bittner’s work have shown promising signs of brain activity with some of the compounds being tested, which Moulton described as “very encouraging.”
Expanding Collaborations and Future Directions
The scope of this research extends beyond Oregon State University, with collaborations underway with several institutions. The team is working with the University of Alberta on morpholino delivery for muscular dystrophies and spinal muscular atrophy, with the University of North Carolina-Chapel Hill on cystic fibrosis, and with the National Institutes of Health and Icahn School of Medicine at Mount Sinai on the Nipah virus, another potentially deadly pathogen.
The potential applications of this technology are broad, offering hope for treatments targeting a wide spectrum of diseases. The ability to precisely control gene expression could revolutionize how we approach conditions ranging from inherited genetic disorders to rapidly evolving infectious diseases.
Looking ahead, the team will continue to refine their delivery platforms and expand their collaborations. The next steps involve further preclinical testing and, clinical trials to assess the safety and efficacy of these morpholino-based therapies in humans. The researchers are actively seeking additional funding to support these critical endeavors.
This research represents a significant step forward in the field of genetic medicine, offering a glimpse into a future where targeted therapies can address the root causes of disease with unprecedented precision. Share your thoughts on this promising research in the comments below.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
